The S&P 500 (^GSPC) has entered correction, falling 10% from its February all-time highs as political uncertainty has driven ...
The Federal Reserve will keep interest rates steady through the first half of the year, before delivering two reductions ...
BMO Capital Markets upgraded shares of goeasy (TSE:GSY – Free Report) from a market perform rating to an outperform rating in ...
Dollarama (TSE:DOL – Get Free Report) had its target price raised by stock analysts at BMO Capital Markets from C$154.00 to ...
Tesla (TSLA) shares are down about 38% this year. But BMO Capital Markets chief investment strategist Brian Belski says ...
On Thursday, BMO Capital Markets sustained their Market Perform rating on Casey’s General Stores (NASDAQ:CASY), with a steady price target of $450.00. The convenience store chain, currently ...
Bank of Montreal’s veteran oil and gas analyst is making the case for a four-way mega merger in Western Canada’s Montney ...
Stock market corrections of 10% hurt. But research shows that they often don't portend worse things ahead for stocks.
BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12 ...
ECN Capital Corp. (TSX: ECN) ("ECN Capital” or the "Company”) today announced that it has entered into an agreement with a syndicate of underwriters (the "Underwriters”) led by CIBC Capital Markets, ...
The revised estimates put Wall Street's average year-end target for the S&P 500 at 6,607, implying an advance of more than 17% from Friday's close of 5,638.94, according to a recent survey of Wall ...
On Tuesday, BMO Capital Markets began coverage of Avidity Biosciences (NASDAQ:RNA) shares, assigning an Outperform rating and setting a price target of $72.00. Currently trading at $29.58, the stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results